Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CYCLOBENZAPRINE Cause Back disorder? 19 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Back disorder have been filed in association with CYCLOBENZAPRINE (Cyclobenzaprine hydrochloride). This represents 0.2% of all adverse event reports for CYCLOBENZAPRINE.

19
Reports of Back disorder with CYCLOBENZAPRINE
0.2%
of all CYCLOBENZAPRINE reports
7
Deaths
11
Hospitalizations

How Dangerous Is Back disorder From CYCLOBENZAPRINE?

Of the 19 reports, 7 (36.8%) resulted in death, 11 (57.9%) required hospitalization, and 6 (31.6%) were considered life-threatening.

Is Back disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CYCLOBENZAPRINE. However, 19 reports have been filed with the FAERS database.

What Other Side Effects Does CYCLOBENZAPRINE Cause?

Toxicity to various agents (1,854) Pain (1,494) Completed suicide (1,438) Drug hypersensitivity (1,094) Constipation (1,057) Drug ineffective (954) Drug abuse (873) Off label use (800) Fall (796) Hypotension (769)

What Other Drugs Cause Back disorder?

ADALIMUMAB (1,159) LENALIDOMIDE (696) ETANERCEPT (651) TOFACITINIB (490) ABATACEPT (481) PREGABALIN (443) METHOTREXATE (416) SECUKINUMAB (325) APREMILAST (317) APIXABAN (309)

Which CYCLOBENZAPRINE Alternatives Have Lower Back disorder Risk?

CYCLOBENZAPRINE vs CYCLOPENTOLATE CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE FOR , USP CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE\DOXORUBICIN\PREDNISONE\RITUXIMAB\VINCRISTINE CYCLOBENZAPRINE vs CYCLOPHOSPHAMIDE\DOXORUBICIN\PREDNISONE\VINCRISTINE

Related Pages

CYCLOBENZAPRINE Full Profile All Back disorder Reports All Drugs Causing Back disorder CYCLOBENZAPRINE Demographics